Identifying and treating hypoglycemia in insulin-treated diabetes

Brian Frier

doi:10.4103/jdep.jdep_11_21

Journal of Diabetes and Endocrine Practice, Table of Contents

CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2021; 04(01): 2-3
DOI: 10.4103/jdep.jdep_11_21

Commentary

Identifying and treating hypoglycemia in insulin-treated diabetes

Brian Frier

The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, Scotland, UK

› Author Affiliations

Abstract

Full Text

References

References
1 International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: A joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017;40:155-7.
2 Frier BM. Hypoglycaemia in diabetes mellitus: Epidemiology and clinical implications. Nat Rev Endocrinol 2014;10:711-22.
3 UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7.
4 Edridge CL, Dunkley AJ, Bodicoat DH, Rose TC, Gray LJ, Davies MJ, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: A systematic review and meta-analysis of population based studies. PLoS One 2015;10:e0126427.
5 Khunti K, Alsifri S, Aronson R, Cigrovski Berković M, Enters-Weijnen C, Forsén T, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: The global HAT study. Diabetes Obes Metab 2016;18:907-15.
6 Pedersen-Bjergaard U, Alsifri S, Aronson R, Berković MC, Galstyan G, Gydesen H, et al. Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies. Diabetes Obes Metab 2019;21:844-53.
7 Al Zahrani AM, Al-Zaidi S, Al Shaikh A, Alghamdi A, Farahat F. Lack of knowledge about hypoglycemia among adult patients with diabetes mellitus in Saudi Arabia: A cross-sectional study. J Diabetes Endocr Pract 2021;4:37-42.
8 Östenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-Bjergaard U. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med 2014;31:92-101.
9 Frier BM, Jensen MM, Chubb BD. Hypoglycaemia in adults with insulin-treated diabetes in the UK: Self-reported frequency and effects. Diabet Med 2016;33:1125-32.
10 McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet Med 2001;18:690-705.
11 Thieu VT, Mitchell BD, Varnado OJ, Frier BM. Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon. Diabetes Obes Metab 2020;22:469-79.
12 Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: A population-based study. Diabet Med 2005;22:749-55.
13 Heba SF, Parveen U, Khanum SS, Gulnaaz M, Tabassum M, Safiyya SB. Nasal. Inhaled glucagon: A new hope for severe hypoglycemia in type 1 diabetes. J Diabetes Endocr Pract 2021;4:14-19.
14 Guzman CB, Dulude H, Piché C, Rufiange M, Sadoune AA, Rampakakis E, et al. Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial. Diabetes Obes Metab 2018;20:646-53.